When time is precious

Initiating Drogenil for metastatic cancer patients could optimise not only time to progression and survival time but also the quality of that life.1-6

As monotherapy, Drogenil is comparable to castration in terms of survival time,7 and unlike castration, Drogenil patients can keep their libido and potency,3,5 helping them to sustain a loving relationship. Drogenil is the only non-steroidal anti-androgen recommended for monotherapy.

As part of combination therapy in maximal androgen blockade (MAB), of all the anti-androgens, including the recently launched bicalutamide, only Drogenil has proven survival advantage over orchidectomy or medical castration1,2 – offering patients the chance of more precious time.